Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 3, Pages 603
Publisher
MDPI AG
Online
2017-03-13
DOI
10.3390/ijms18030603
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Drug and Possible New Toxicity – Squamous Cell Carcinoma Following Imatinib in Patients with Gastrointestinal Stromal Tumors
- (2016) FAISAL INAYAT et al. ANTICANCER RESEARCH
- A pharmacogenomic study on the pharmacokinetics of tacrolimus in healthy subjects using the DMETTM Plus platform
- (2016) Y Choi et al. PHARMACOGENOMICS JOURNAL
- The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
- (2015) Toshirou Nishida et al. Gastric Cancer
- Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor
- (2014) Dong-Hoe Koo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis
- (2014) Q Zheng et al. PHARMACOGENOMICS JOURNAL
- Gastrointestinal Stromal Tumors, Somatic Mutations and Candidate Genetic Risk Variants
- (2013) Katie M. O'Brien et al. PLoS One
- Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
- (2012) Bo Gao et al. JOURNAL OF CLINICAL ONCOLOGY
- The safety profile of imatinib in CML and GIST: long-term considerations
- (2011) Eirini Thanopoulou et al. ARCHIVES OF TOXICOLOGY
- The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors
- (2011) Steven Lane et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Moving towards dose individualization of tyrosine kinase inhibitors
- (2010) Heinz-Josef Klümpen et al. CANCER TREATMENT REVIEWS
- Drug Transporters and Imatinib Treatment: Implications for Clinical Practice
- (2010) K. Eechoute et al. CLINICAL CANCER RESEARCH
- Cross-Sectional Study of Imatinib Plasma Trough Levels in Patients With Advanced Gastrointestinal Stromal Tumors: Impact of Gastrointestinal Resection on Exposure to Imatinib
- (2010) Changhoon Yoo et al. JOURNAL OF CLINICAL ONCOLOGY
- Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate
- (2009) Jonathan C. Trent et al. CANCER
- Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors
- (2009) George D. Demetri et al. JOURNAL OF CLINICAL ONCOLOGY
- Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients
- (2009) J. Du et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability
- (2008) N Widmer et al. BRITISH JOURNAL OF CANCER
- The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib
- (2008) Roos L. Oostendorp et al. INVESTIGATIONAL NEW DRUGS
- Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
- (2008) Charles D. Blanke et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started